GENERAL INFORMATION
Collaborative Research Centre
TRR 295 ReTune
Our TRR 295 seeks to improve the understanding of the various symptoms of human movement disorders by elucidating symptom-specific neural activity and developing specific treatment strategies for network modulation in common and clinically-relevant neurological diseases. We hypothesize that neuromodulation is a promising tool that can modify network activity and restore motor function by eliminating pathological network activity, augmenting normal interareal communication, or activating compensatory circuits. …
News & Events
Experimental Neurology Special Issue: Neuromodulation
February 17, 2022
Edited by Andrea A. Kühn & Jens Volkmann.
ReTune Neuroscience Colloquium: Hartwig Siebner
June 2, 2022 | 5 pm | Zoom
Precision targeting of large-scale brain circuits with transcranial magnetic stimulation.
ReTune Retreat 2022
April 28-29, 2022 | Esplanade Bad Saarow
Registration is now open (invitation via mailing list) until March 31.
Publications
Electrophysiological characterization of the hyperdirect pathway and its functional relevance for subthalamic deep brain stimulation
The subthalamic nucleus (STN) receives input from various cortical areas via hyperdirect pathway (HDP) which bypasses the basal-ganglia loop. Recently, the HDP has gained increasing interest, because of its relevance for STN deep brain stimulation (DBS). To understand the HDP's role cortical responses evoked by STN-DBS have been investigated. ...
Published: 2022 Mar
Real-time phase and amplitude estimation of neurophysiological signals exploiting a non-resonant oscillator
A recent advancement in the field of neuromodulation is to adapt stimulation parameters according to pre-specified biomarkers tracked in real-time. These markers comprise short and transient signal features, such as bursts of elevated band power. ...
Published: 2022 Jan
Experimental deep brain stimulation in rodent models of movement disorders
Deep brain stimulation (DBS) is the preferred treatment for therapy-resistant movement disorders such as dystonia and Parkinson's disease (PD), mostly in advanced disease stages. Although DBS is already in clinical use for ~30 years and has improved patients' quality of life dramatically, there is still limited understanding of the underlying mechanisms of action. Rodent models of PD and dystonia are essential tools to elucidate the mode of action of DBS on behavioral and multiscale neurobiological levels. ...
Published: 2022 Jan
